Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

222 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Alexanian R, et al. Semin Oncol. 2003 Apr;30(2):206-10. doi: 10.1053/sonc.2003.50051. Semin Oncol. 2003. PMID: 12720137
How we treat Waldenström's macroglobulinemia.
Dimopoulos MA, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R. Dimopoulos MA, et al. Haematologica. 2005 Jan;90(1):117-25. Haematologica. 2005. PMID: 15642678 Review.
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM. Dimopoulos MA, et al. Leuk Lymphoma. 2004 Oct;45(10):2057-61. doi: 10.1080/10428190410001723287. Leuk Lymphoma. 2004. PMID: 15370250 Clinical Trial.
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V. Kyle RA, et al. Semin Oncol. 2003 Apr;30(2):116-20. doi: 10.1053/sonc.2003.50038. Semin Oncol. 2003. PMID: 12720119 Review.
Differential diagnosis of monoclonal gammopathies.
Alexanian R, Weber D, Liu F. Alexanian R, et al. Arch Pathol Lab Med. 1999 Feb;123(2):108-13. doi: 10.1043/0003-9985(1999)123<0108:DDOMG>2.0.CO;2. Arch Pathol Lab Med. 1999. PMID: 10050782 Review.
Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R 3rd, Breitz H, Alexanian R, Champlin R, Giralt S. Christoforidou AV, et al. Biol Blood Marrow Transplant. 2007 May;13(5):543-9. doi: 10.1016/j.bbmt.2006.12.448. Epub 2007 Feb 26. Biol Blood Marrow Transplant. 2007. PMID: 17448913
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Garcia MK, et al. Among authors: alexanian r. J Hematol Oncol. 2014 May 9;7:41. doi: 10.1186/1756-8722-7-41. J Hematol Oncol. 2014. PMID: 24886772 Free PMC article. Clinical Trial.
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Fu W, Delasalle K, Wang J, Song S, Hou J, Alexanian R, Wang M. Fu W, et al. Am J Clin Oncol. 2012 Dec;35(6):562-5. doi: 10.1097/COC.0b013e31822043f6. Am J Clin Oncol. 2012. PMID: 21694573
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.
Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Reed V, et al. Cancer. 2011 Oct 1;117(19):4468-74. doi: 10.1002/cncr.26031. Epub 2011 Mar 22. Cancer. 2011. PMID: 21437886
222 results
Jump to page
Feedback